Department of Neurology, Yonsei University College of Medicine, Seoul, Korea.
Eur J Neurol. 2012 Mar;19(3):473-9. doi: 10.1111/j.1468-1331.2011.03547.x. Epub 2011 Oct 4.
The CHADS(2) and CHA(2) DS(2) -VASc scores are useful to stratify embolic risks in patients with non-valvular atrial fibrillation (NVAF) and to identify patients eligible for anticoagulation. Although the risk of stoke increases in patients with higher CHADS(2) or CHA(2) DS(2) -VASc scores, it is uncertain why the stroke rate increases in them. Concomitant potential cardiac sources of embolism (PCSE) may be more frequent in patients with higher CHADS(2) or CHA(2) DS(2) -VASc scores because stroke risks increase when concomitant PCSE is present in Atrial fibrillation (AF). On the other hand, atherothrombosis may be the cause when considering that most components of the CHADS(2) and CHA(2) DS(2) -VASc scores are risk factors for atherosclerosis.
Amongst 5493 stroke patients who were prospectively registered with the stroke registry for 11years, 860 consecutive patients with NVAF were included for this study. We investigated the mechanisms of stroke according to the CHADS(2) /CHA(2) DS(2) -VASc score in stroke patients with NVAF.
Amongst 860 patients, concomitant PCSE were found in 334 patients (38.8%). The number of PCSE increased as the CHADS(2) /CHA(2) DS(2) -VASc score increased (P<0.001). Of individual PCSE, akinetic left ventricular segment, hypokinetic left ventricular segment and myocardial infarction <4weeks were associated with the CHADS(2) /CHA(2) DS(2) -VASc score. The presence of possible atherothrombotic mechanism, in addition to AF, was suggested in 27.3%. The proportion of patients with concomitant presence of possible atherothrombosis was increased as the CHADS(2) /CHA(2) DS(2) -VASc score increased (P<0.001).
Increased frequency of concomitant PCSE and that of the atherothrombotic mechanism may explain the high risk of stroke in patients with higher CHADS(2) /CHA(2) DS(2) -VASc score.
CHADS(2)和CHA(2)DS(2)-VASc 评分有助于对非瓣膜性心房颤动(NVAF)患者进行栓塞风险分层,并确定适合抗凝治疗的患者。尽管 CHADS(2)或 CHA(2)DS(2)-VASc 评分较高的患者发生中风的风险增加,但尚不清楚为什么这些患者的中风率会增加。由于当 NVAF 患者存在伴随性心源性栓塞源(PCSE)时,中风风险会增加,因此,CHADS(2)或 CHA(2)DS(2)-VASc 评分较高的患者可能会更频繁地出现伴随性 PCSE。另一方面,考虑到 CHADS(2)和 CHA(2)DS(2)-VASc 评分的大多数组成部分都是动脉粥样硬化的危险因素,因此动脉血栓形成可能是导致中风的原因。
在前瞻性登记的 11 年中风登记中,共有 5493 名中风患者,本研究纳入了其中 860 名连续的 NVAF 中风患者。我们根据 NVAF 中风患者的 CHADS(2)/CHA(2)DS(2)-VASc 评分,研究了中风的发病机制。
在 860 名患者中,有 334 名患者(38.8%)存在伴随性 PCSE。随着 CHADS(2)/CHA(2)DS(2)-VASc 评分的增加,PCSE 的数量也随之增加(P<0.001)。在个体 PCSE 中,无运动的左心室节段、运动不足的左心室节段和<4 周的心肌梗死与 CHADS(2)/CHA(2)DS(2)-VASc 评分相关。除了 AF 之外,还提示存在可能的动脉血栓形成机制,占 27.3%。随着 CHADS(2)/CHA(2)DS(2)-VASc 评分的增加,同时存在可能的动脉粥样硬化的患者比例也增加(P<0.001)。
伴随性 PCSE 发生率和动脉血栓形成机制的增加可能解释了 CHADS(2)/CHA(2)DS(2)-VASc 评分较高的患者中风风险较高的原因。